Validity of Patient-Reported Outcome Measures in Evaluating Nerve Damage Following Chemotherapy.

ABSTRACT:

Importance

Chemotherapy-induced peripheral neuropathy (CIPN) is a substantial adverse effect of anticancer treatments. As such, the assessment of CIPN remains critically important in both research and clinic settings.

Objective

To compare the validity of various patient-reported outcome measures (PROMs) with neurophysiological and sensory functional measures as the optimal method of CIPN assessment.

Design, setting, and participants

This cohort study evaluated participants treated with neurotoxic chemotherapy across 2 cohorts using a dual-study design. Participants commencing treatment were assessed prospectively at beginning of neurotoxic treatment, midtreatment, and at the end of treatment. Participants who completed treatment up to 5 years prior were assessed cross

SUBMITTER: Li T 

PROVIDER: S-EPMC11316238 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature